Literature DB >> 19962457

Somatic mutations in PI3Kalpha: structural basis for enzyme activation and drug design.

Sandra B Gabelli1, Diana Mandelker, Oleg Schmidt-Kittler, Bert Vogelstein, L Mario Amzel.   

Abstract

The PI3K pathway is a communication hub coordinating critical cell functions including cell survival, cell growth, proliferation, motility and metabolism. Because PI3Kalpha harbors recurrent somatic mutations resulting in gains of function in human cancers, it has emerged as an important drug target for many types of solid tumors. Various PI3K isoforms are also being evaluated as potential therapeutic targets for inflammation, heart disease, and hematological malignancies. Structural biology is providing insights into the flexibility of the PI3Ks, and providing basis for understanding the effects of mutations, drug resistance and specificity. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19962457      PMCID: PMC2821964          DOI: 10.1016/j.bbapap.2009.11.020

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  52 in total

1.  Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas.

Authors:  Enrique Lerma; Lluis Catasus; Alberto Gallardo; Gloria Peiro; Carmen Alonso; Ignacio Aranda; Agusti Barnadas; Jaime Prat
Journal:  Virchows Arch       Date:  2008-08-05       Impact factor: 4.064

2.  Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity.

Authors:  Peng Xie; Douglas S Williams; G Ekin Atilla-Gokcumen; Leslie Milk; Min Xiao; Keiran S M Smalley; Meenhard Herlyn; Eric Meggers; Ronen Marmorstein
Journal:  ACS Chem Biol       Date:  2008-05-16       Impact factor: 5.100

3.  The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma.

Authors:  Julie Guillermet-Guibert; Katja Bjorklof; Ashreena Salpekar; Cristiano Gonella; Faruk Ramadani; Antonio Bilancio; Stephen Meek; Andrew J H Smith; Klaus Okkenhaug; Bart Vanhaesebroeck
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-10       Impact factor: 11.205

4.  Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.

Authors:  Sauveur-Michel Maira; Frédéric Stauffer; Josef Brueggen; Pascal Furet; Christian Schnell; Christine Fritsch; Saskia Brachmann; Patrick Chène; Alain De Pover; Kevin Schoemaker; Doriano Fabbro; Daniela Gabriel; Marjo Simonen; Leon Murphy; Peter Finan; William Sellers; Carlos García-Echeverría
Journal:  Mol Cancer Ther       Date:  2008-07-07       Impact factor: 6.261

5.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

6.  Achieving multi-isoform PI3K inhibition in a series of substituted 3,4-dihydro-2H-benzo[1,4]oxazines.

Authors:  Benjamin Perry; Rikki Alexander; Gavin Bennett; George Buckley; Tom Ceska; Tom Crabbe; Verity Dale; Lewis Gowers; Helen Horsley; Lynwen James; Kerry Jenkins; Karen Crépy; Claire Kulisa; Helen Lightfoot; Chris Lock; Stephen Mack; Trevor Morgan; Anne-Lise Nicolas; Will Pitt; Verity Sabin; Sara Wright
Journal:  Bioorg Med Chem Lett       Date:  2008-07-05       Impact factor: 2.823

7.  The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .

Authors:  Adrian J Folkes; Khatereh Ahmadi; Wendy K Alderton; Sonia Alix; Stewart J Baker; Gary Box; Irina S Chuckowree; Paul A Clarke; Paul Depledge; Suzanne A Eccles; Lori S Friedman; Angela Hayes; Timothy C Hancox; Arumugam Kugendradas; Letitia Lensun; Pauline Moore; Alan G Olivero; Jodie Pang; Sonal Patel; Giles H Pergl-Wilson; Florence I Raynaud; Anthony Robson; Nahid Saghir; Laurent Salphati; Sukhjit Sohal; Mark H Ultsch; Melanie Valenti; Heidi J A Wallweber; Nan Chi Wan; Christian Wiesmann; Paul Workman; Alexander Zhyvoloup; Marketa J Zvelebil; Stephen J Shuttleworth
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

8.  Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms.

Authors:  Li Zhao; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-11       Impact factor: 11.205

9.  PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters.

Authors:  Lluis Catasus; Alberto Gallardo; Miriam Cuatrecasas; Jaime Prat
Journal:  Mod Pathol       Date:  2007-12-14       Impact factor: 7.842

10.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors: 
Journal:  Nature       Date:  2008-09-04       Impact factor: 49.962

View more
  8 in total

Review 1.  Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review.

Authors:  Priyanka Singh; Veerandra Kumar; Sonu Kumar Gupta; Gudia Kumari; Malkhey Verma
Journal:  Med Oncol       Date:  2021-01-16       Impact factor: 3.064

Review 2.  Capitalizing on tumor genotyping: towards the design of mutation specific inhibitors of phosphoinsitide-3-kinase.

Authors:  Sandra B Gabelli; Krisna C Duong-Ly; Evan T Brower; L Mario Amzel
Journal:  Adv Enzyme Regul       Date:  2010-10-28

3.  Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.

Authors:  Ignacia Echeverria; Yunlong Liu; Sandra B Gabelli; L Mario Amzel
Journal:  FEBS J       Date:  2015-07-24       Impact factor: 5.542

4.  Class I PI3K Biology.

Authors:  Tihitina Y Aytenfisu; Hannah M Campbell; Mayukh Chakrabarti; L Mario Amzel; Sandra B Gabelli
Journal:  Curr Top Microbiol Immunol       Date:  2022       Impact factor: 4.737

5.  Activation of PI3Kα by physiological effectors and by oncogenic mutations: structural and dynamic effects.

Authors:  Sandra B Gabelli; Ignacia Echeverria; Megan Alexander; Krisna C Duong-Ly; Daniele Chaves-Moreira; Evan T Brower; B Vogelstein; L Mario Amzel
Journal:  Biophys Rev       Date:  2014-03-01

Review 6.  Impact of p85α Alterations in Cancer.

Authors:  Jeremy D S Marshall; Dielle E Whitecross; Paul Mellor; Deborah H Anderson
Journal:  Biomolecules       Date:  2019-01-15

7.  Nanobodies and chemical cross-links advance the structural and functional analysis of PI3Kα.

Authors:  Jonathan R Hart; Xiao Liu; Chen Pan; Anyi Liang; Lynn Ueno; Yingna Xu; Alexandra Quezada; Xinyu Zou; Su Yang; Qingtong Zhou; Steve Schoonooghe; Gholamreza Hassanzadeh-Ghassabeh; Tian Xia; Wenqing Shui; Dehua Yang; Peter K Vogt; Ming-Wei Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2022-09-12       Impact factor: 12.779

8.  PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer.

Authors:  Siv Mjos; Henrica M J Werner; Even Birkeland; Frederik Holst; Anna Berg; Mari K Halle; Ingvild L Tangen; Kanthida Kusonmano; Karen K Mauland; Anne M Oyan; Karl-Henning Kalland; Aurélia E Lewis; Gordon B Mills; Camilla Krakstad; Jone Trovik; Helga B Salvesen; Erling A Hoivik
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.